DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 13.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,959 shares of the medical device company’s stock after selling 2,674 shares during the quarter. Van ECK Associates Corp’s holdings in DexCom were worth $2,229,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Stableford Capital II LLC boosted its position in shares of DexCom by 2.1% in the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares in the last quarter. Valley National Advisers Inc. lifted its position in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the period. FORVIS Wealth Advisors LLC lifted its position in DexCom by 0.7% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares during the period. Cary Street Partners Investment Advisory LLC lifted its position in DexCom by 11.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after acquiring an additional 115 shares during the period. Finally, HM Payson & Co. lifted its position in DexCom by 8.5% during the 3rd quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock worth $138,000 after acquiring an additional 116 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $130.10 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The business has a 50-day moving average price of $132.67 and a 200 day moving average price of $121.11. The firm has a market cap of $51.74 billion, a PE ratio of 83.94, a P/E/G ratio of 2.19 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. Sell-side analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on DXCM shares. Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Citigroup lifted their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Canaccord Genuity Group lifted their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 190,004 shares of company stock worth $25,610,270. Insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.